Drostanolone (Masteron): DHT Derivative Research Profile

Research Disclaimer: All compounds described are sold exclusively for in-vitro and laboratory research use. Not for unsupervised use. This content does not constitute medical advice.

Drostanolone (2α-methyl-dihydrotestosterone; brand name Masteron) is a synthetic androgen derived from 5α-dihydrotestosterone (DHT) with a 2α-methyl modification. Available as drostanolone propionate (t½ ~2.5 days) and drostanolone enanthate (t½ ~7–10 days), drostanolone has unique research properties: it is non-aromatizing, moderately anabolic (A:A ratio ~60:1), and possesses anti-estrogenic activity via partial estrogen receptor (ER) antagonism and possible aromatase competition. Originally developed for the treatment of inoperable breast cancer, it remains a pharmacologically interesting research compound for androgen-estrogen interaction studies.

Table of Contents#

1. Structure: 2α-Methyl-DHT Chemistry
2. Pharmacokinetics: Propionate vs. Enanthate
3. Anti-Estrogenic Properties
4. AR Binding and Anabolic Activity
5. Historical Clinical Use: Breast Cancer
6. Body Composition Research Profile
7. Research Protocols
8. Key References

Structure: 2α-Methyl-DHT Chemistry#

DHT scaffold:

• Drostanolone is built on the 5α-dihydrotestosterone (DHT) scaffold: A ring fully saturated (no Δ4-3-ketone), 17β-OH
• 5α-reduced: not a substrate for 5α-reductase (already reduced) → no further DHT conversion
• Not a substrate for aromatase (no Δ4-3-ketone in ring A required for aromatase substrate recognition)

2α-Methyl modification:

• Methyl group at C2α position → blocks 3α/3β-HSD reduction of the 3-keto group → prevents inactivation
• Also contributes steric bulk near the A ring → increases resistance to metabolic inactivation
• Result: longer tissue half-life than DHT itself (which is rapidly inactivated to 3α-androstanediol by 3α-HSD)

Esters:

• Drostanolone propionate: 3-carbon ester → very fast ester hydrolysis → short t½ ~2.5 days
• Drostanolone enanthate: 7-carbon ester → t½ ~7–10 days

Pharmacokinetics: Propionate vs. Enanthate#

SHBG note: DHT derivatives bind SHBG with high affinity, but once drostanolone occupies SHBG, it reduces the SHBG available to bind testosterone → increases free testosterone fraction. This SHBG displacement is part of its research interest in testosterone-amplification models.

Anti-Estrogenic Properties#

Drostanolone's anti-estrogenic activity is well-documented:

Mechanisms:

1. Partial ER antagonism: Drostanolone and its metabolites bind estrogen receptors (ERα/β) with partial antagonist activity in some tissues → competes with E2 for ER binding → reduces E2 transcriptional activity
2. Aromatase competition (substrate-level): Drostanolone may competitively inhibit aromatase substrate binding → reduces E2 production from testosterone → anti-estrogenic effect at source
3. SHBG displacement → reduces E2: By occupying SHBG, drostanolone may displace E2 from SHBG → increased free E2 clearance (this mechanism is debated in literature)

Historical evidence:

• Drostanolone was used as a palliative treatment for inoperable ER-positive breast cancer in premenopausal women — its anti-estrogenic effect was the rationale
• Clinical response rates: ~30–40% (partial responses) in ER+ breast cancer before tamoxifen era
• Mechanistically replaced by tamoxifen (more potent ER antagonist) and aromatase inhibitors

Research application: Drostanolone remains useful for studying androgen-estrogen crosstalk, especially in models where testosterone + aromatase is the E2 source and a non-AI anti-estrogenic agent is desired.

AR Binding and Anabolic Activity#

AR affinity:

• Drostanolone relative binding affinity: ~40–60% of DHT (which is ~300% of testosterone)
• Still significantly higher than testosterone (~100% reference)
• No progestogenic activity (unlike nandrolone); anti-progestogenic in some models

A:A ratio (Hershberger assay):

• Levator ani / ventral prostate: ~60:1 relative to testosterone
• Highly androgenic in androgenic tissues (prostate stimulation is a concern at high doses)
• Anabolic activity in levator ani at lower relative doses than androgenic effects

SHBG binding:

• Drostanolone has moderately high SHBG affinity (~30% of DHT)
• Occupies SHBG → reduces SHBG available → increases free testosterone/free DHT

Historical Clinical Use: Breast Cancer#

Timeline:

• 1950s–1970s: Drostanolone used as palliative therapy for metastatic breast cancer
• Rationale: ER+ breast cancer → anti-estrogenic androgens may inhibit tumor growth
• Dose studied: 100 mg IM 3× weekly (propionate); high androgen dose was needed for tumor control
• Response rate: ~30–40% partial responses; complete responses rare
• Side effects limiting clinical use: virilization in female patients at doses needed for efficacy
• Replaced by tamoxifen (1977 FDA approval) → more effective, better tolerated, oral

Lessons for research:

• The breast cancer indication confirms drostanolone's ER antagonist activity in vivo
• High androgenic burden at therapeutic anti-estrogenic doses limits the clinical utility
• For research: lower doses can be used to study partial ER antagonism without full virilization

Body Composition Research Profile#

Comparative A:A profile:

• Anabolic potency: approximately 3× testosterone per mg (based on LBM effects in animal models)
• Fat-free mass increase in castrated rat: similar to stanozolol at equivalent doses
• No water retention (non-aromatizing → no E2-driven fluid retention)
• No progestogen-mediated effects → no progesterone-receptor water retention

Muscle fiber research:

• DHT derivatives predominantly affect Type II fast-twitch fibers (high AR density)
• Drostanolone: cross-sectional area increase in Type II fibers > Type I in animal models
• Consistent with DHT's role in explosive/strength-type muscle development

Research Protocols#

Body composition study: drostanolone propionate vs. stanozolol (castrated rats)#

ER antagonism assay: drostanolone vs. tamoxifen in MCF-7 cells#

Key References#

1. Lippman ME, et al. (1976). "Androgen and glucocorticoid receptors in human breast cancer." Cancer Research, 36(12):4610–4618.

2. Gao W, et al. (2005). "Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex." Endocrine Reviews, 26(3):290–322.

3. Saartok T, et al. (1984). "Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate." Endocrinology, 114(6):2100–2106.

Research Use Only: Drostanolone is sold exclusively for in-vitro research and laboratory use. Not for unsupervised use. JuicedPharma does not provide medical advice.

Published by JuicedPharma Research Team · September 2026 · Category: Research Protocols & Science